{"id":32358,"date":"2025-02-20T08:03:59","date_gmt":"2025-02-20T08:03:59","guid":{"rendered":"https:\/\/triniti.eu\/?post_type=experience&#038;p=32358"},"modified":"2025-02-20T08:08:57","modified_gmt":"2025-02-20T08:08:57","slug":"svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija","status":"publish","type":"experience","link":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/","title":{"rendered":"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105"},"content":{"rendered":"<p style=\"font-weight: 400;\">Biotechnologij\u0173 startuolis \u201e<a href=\"https:\/\/atrandi.com\/\">Atrandi Biosciences<\/a>\u201c, viena pirm\u0173j\u0173 pasaulyje \u012fmoni\u0173, kurian\u010di\u0173 pa\u017eangias pavieni\u0173 l\u0105steli\u0173 analiz\u0117s technologijas, pritrauk\u0117 25 milijon\u0173 JAV doleri\u0173 investicij\u0105 A serijos finansavimo etape. Pagrindiniu investuotoju tapo JAV rizikos kapitalo fondas \u201eLux Capital\u201c, kuris specializuojasi inovatyvi\u0173 technologij\u0173 srityje. Taip pat prie finansavimo prisijung\u0117 esami ir nauji investuotojai: \u201eVsquared Ventures\u201c, \u201ePractica Capital\u201c, \u201eMetaplanet\u201c ir \u201eGRIDS Capital\u201c. \u0160i investicija paspartins \u012fmon\u0117s pl\u0117tr\u0105 JAV rinkoje, pad\u0117s pl\u0117toti <a href=\"https:\/\/atrandi.com\/technology\/semi-permeable-capsules\">pusiau pralaid\u017ei\u0173 kapsuli\u0173<\/a> (angl. <em>Semi-Permeable Capsule<\/em>, SPC) technologij\u0105 bei vystyti nauj\u0173 produkt\u0173 k\u016brim\u0105.<\/p>\n<p style=\"font-weight: 400;\">\u201eKai 2016 metais \u012fk\u016br\u0117me \u201eAtrandi Biosciences\u201c, m\u016bs\u0173 tikslas buvo pa\u0161alinti esmines biologini\u0173 tyrim\u0173 kli\u016btis ir sukurti efektyvius bei lengvai pritaikomus \u012frankius pavieni\u0173 l\u0105steli\u0173 analizei\u201c, \u2013 sako dr. Juozas Nainys, \u201eAtrandi Biosciences\u201c generalinis direktorius ir vienas i\u0161 \u012fk\u016br\u0117j\u0173. \u201eM\u016bs\u0173 sukurta SPC technologija kardinaliai kei\u010dia pavieni\u0173 l\u0105steli\u0173 analiz\u0117s galimybes, suteikdama mokslininkams priemones generuoti itin auk\u0161tos kokyb\u0117s biologinius duomenis. \u0160i investicija pad\u0117s mums pl\u0117sti produkt\u0173 portfel\u012f, stiprinti pozicijas JAV rinkoje ir geriau r\u016bpintis savo klientais. M\u016bs\u0173 misija \u2013 suteikti mokslininkams pa\u017eangius \u012frankius, kurie atvers naujas biologijos mokslo galimybes.\u201c<\/p>\n<p style=\"font-weight: 400;\">\u201eTriniti Jurex\u201c komanda atliko esmin\u012f vaidmen\u012f \u0161iame investiciniame sandoryje, u\u017etikrindama, kad visi teisiniai aspektai b\u016bt\u0173 tinkamai strukt\u016bruoti ir suderinti su tarptautiniais standartais. Sandoris ap\u0117m\u0117 sud\u0117tingus procesus, tokius kaip konvertuojam\u0173 paskol\u0173 pertvarkymas, akcij\u0173 perskirstymas tarp steig\u0117j\u0173 ir investuotoj\u0173 bei nauj\u0173 akcij\u0173 i\u0161leidimas. M\u016bs\u0173 ekspertai dirbo su investuotojais i\u0161 JAV, Vokietijos, Estijos ir Lietuvos, siekdami sukurti skaidri\u0105 ir tvari\u0105 teisin\u0119 strukt\u016br\u0105, kuri suteikia ai\u0161k\u0173 augimo plan\u0105 ir u\u017etikrina ilgalaik\u012f bendrov\u0117s pl\u0117tim\u0105si globalioje rinkoje.<\/p>\n<p style=\"font-weight: 400;\"><strong>Apie \u201eAtrandi Biosciences\u201c<\/strong><\/p>\n<p style=\"font-weight: 400;\">\u201eAtrandi Biosciences\u201c \u2013 pirmieji pasaulyje, kuriantys pusiau pralaid\u017ei\u0173 kapsuli\u0173 technologij\u0105, kuri leid\u017eia vykdyti didelio masto vienos l\u0105stel\u0117s multiomikos tyrimus. \u012emon\u0117s patentuoti sprendimai supaprastina sud\u0117tingus eksperimentinius procesus ir paspartina biologinius atradimus. \u201eAtrandi Biosciences\u201c misija \u2013 suteikti mokslininkams pa\u017eangius \u012frankius, padedan\u010dius geriau suprasti gyvyb\u0117s kompleksi\u0161kum\u0105 ir atskleisti dar nepa\u017eintus biologinius procesus.<\/p>\n<p style=\"font-weight: 400;\"><strong>Daugiau informacijos: <a href=\"https:\/\/atrandi.com\/\">https:\/\/atrandi.com\/<\/a><\/strong><\/p>\n","protected":false},"featured_media":0,"template":"","experience_practice_area":[277,289],"person_countries":[644,248],"people_industries":[415],"class_list":["post-32358","experience","type-experience","status-publish","hentry","experience_practice_area-imoniu-teise-susijungimai-ir-isigijimai","experience_practice_area-privatus-kapitalas-rizikos-kapitalas-ir-startuoliai","person_countries-all-lt","person_countries-lietuva","people_industries-startuoliai"],"acf":{"experience_photo":32359,"og_photo":32366,"experience_related_people":[9077,3858,3878],"translated":"Translated"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105 | TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/\" \/>\n<meta property=\"og:locale\" content=\"lt_LT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105 | TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora\" \/>\n<meta property=\"og:description\" content=\"Biotechnologij\u0173 startuolis \u201eAtrandi Biosciences\u201c, viena pirm\u0173j\u0173 pasaulyje \u012fmoni\u0173, kurian\u010di\u0173 pa\u017eangias pavieni\u0173 l\u0105steli\u0173 analiz\u0117s technologijas, pritrauk\u0117 25 milijon\u0173 JAV doleri\u0173 investicij\u0105 A serijos finansavimo etape. Pagrindiniu investuotoju tapo JAV rizikos kapitalo fondas \u201eLux Capital\u201c, kuris specializuojasi inovatyvi\u0173 technologij\u0173 srityje. Taip pat prie finansavimo prisijung\u0117 esami ir nauji investuotojai: \u201eVsquared Ventures\u201c, \u201ePractica Capital\u201c, \u201eMetaplanet\u201c ir \u201eGRIDS Capital\u201c. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/\" \/>\n<meta property=\"og:site_name\" content=\"TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-20T08:08:57+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minut\u0117s\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/\",\"url\":\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/\",\"name\":\"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105 | TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora\",\"isPartOf\":{\"@id\":\"https:\/\/triniti.eu\/#website\"},\"datePublished\":\"2025-02-20T08:03:59+00:00\",\"dateModified\":\"2025-02-20T08:08:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/#breadcrumb\"},\"inLanguage\":\"lt-LT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/triniti.eu\/lt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/triniti.eu\/#website\",\"url\":\"https:\/\/triniti.eu\/\",\"name\":\"TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora\",\"description\":\"The Future On Your Terms\",\"publisher\":{\"@id\":\"https:\/\/triniti.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/triniti.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"lt-LT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/triniti.eu\/#organization\",\"name\":\"Triniti\",\"url\":\"https:\/\/triniti.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\/\/triniti.eu\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/triniti.eu\/wp-content\/uploads\/2021\/12\/triniti-logo-en.svg\",\"contentUrl\":\"https:\/\/triniti.eu\/wp-content\/uploads\/2021\/12\/triniti-logo-en.svg\",\"width\":400,\"height\":117,\"caption\":\"Triniti\"},\"image\":{\"@id\":\"https:\/\/triniti.eu\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105 | TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/","og_locale":"lt_LT","og_type":"article","og_title":"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105 | TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora","og_description":"Biotechnologij\u0173 startuolis \u201eAtrandi Biosciences\u201c, viena pirm\u0173j\u0173 pasaulyje \u012fmoni\u0173, kurian\u010di\u0173 pa\u017eangias pavieni\u0173 l\u0105steli\u0173 analiz\u0117s technologijas, pritrauk\u0117 25 milijon\u0173 JAV doleri\u0173 investicij\u0105 A serijos finansavimo etape. Pagrindiniu investuotoju tapo JAV rizikos kapitalo fondas \u201eLux Capital\u201c, kuris specializuojasi inovatyvi\u0173 technologij\u0173 srityje. Taip pat prie finansavimo prisijung\u0117 esami ir nauji investuotojai: \u201eVsquared Ventures\u201c, \u201ePractica Capital\u201c, \u201eMetaplanet\u201c ir \u201eGRIDS Capital\u201c. [&hellip;]","og_url":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/","og_site_name":"TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora","article_modified_time":"2025-02-20T08:08:57+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minut\u0117s"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/","url":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/","name":"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105 | TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora","isPartOf":{"@id":"https:\/\/triniti.eu\/#website"},"datePublished":"2025-02-20T08:03:59+00:00","dateModified":"2025-02-20T08:08:57+00:00","breadcrumb":{"@id":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/#breadcrumb"},"inLanguage":"lt-LT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/triniti.eu\/lt\/patirtis\/svarbus-biotechnologiju-sektoriaus-etapas-atstovavome-atrandi-biosciences-pritraukiant-25-mln-jav-doleriu-investicija\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/triniti.eu\/lt\/"},{"@type":"ListItem","position":2,"name":"Svarbus biotechnologij\u0173 sektoriaus etapas \u2013 atstovavome \u201eAtrandi Biosciences\u201c pritraukiant 25 mln. JAV doleri\u0173 investicij\u0105"}]},{"@type":"WebSite","@id":"https:\/\/triniti.eu\/#website","url":"https:\/\/triniti.eu\/","name":"TRINITI JUREX - Baltijos \u0161ali\u0173 advokat\u0173 kontora","description":"The Future On Your Terms","publisher":{"@id":"https:\/\/triniti.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/triniti.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"lt-LT"},{"@type":"Organization","@id":"https:\/\/triniti.eu\/#organization","name":"Triniti","url":"https:\/\/triniti.eu\/","logo":{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/triniti.eu\/#\/schema\/logo\/image\/","url":"https:\/\/triniti.eu\/wp-content\/uploads\/2021\/12\/triniti-logo-en.svg","contentUrl":"https:\/\/triniti.eu\/wp-content\/uploads\/2021\/12\/triniti-logo-en.svg","width":400,"height":117,"caption":"Triniti"},"image":{"@id":"https:\/\/triniti.eu\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/experience\/32358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/experience"}],"about":[{"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/types\/experience"}],"acf:post":[{"embeddable":true,"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/people\/3858"},{"embeddable":true,"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/people\/9077"}],"wp:attachment":[{"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/media?parent=32358"}],"wp:term":[{"taxonomy":"experience_practice_area","embeddable":true,"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/experience_practice_area?post=32358"},{"taxonomy":"person_countries","embeddable":true,"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/person_countries?post=32358"},{"taxonomy":"people_industries","embeddable":true,"href":"https:\/\/triniti.eu\/lt\/wp-json\/wp\/v2\/people_industries?post=32358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}